Pearl Therapeutics Inc
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Pearl Therapeutics Inc chose not to state its revenue in its newest notice of a funding round (Nov 2012).
SEC Form D · Nov 2012
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2012
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Pearl Therapeutics Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Chadwick Orevillo | Executive officer | Nov 2012 |
| Charles Bramlage | Executive officer | Nov 2012 |
| Colin Reisner | Executive officer | Nov 2012 |
| Michael Golden | Executive officer | Nov 2012 |
| Sarvajna Dwivedi | Executive officer | Nov 2012 |
| William Picht, Jr. | Executive officer | Nov 2012 |
| Howard Rosen | Executive officer | Nov 2010 |
| Charles Bramlage | Director | Nov 2012 |
| Howard B. Rosen | Director | Nov 2012 |
| James B. Niedel | Director | Nov 2012 |
| James W. Young | Director | Nov 2012 |
| Kevin B. Ferro | Director | Nov 2012 |
| Nicholas J. Simon | Director | Nov 2012 |
| Steven B. Jaharis | Director | Nov 2012 |
| Sundar Kodiyalam | Director | Nov 2012 |
| Thomas B. Koestler | Director | Nov 2012 |
| Howard Rosen | Director | Nov 2010 |
| James Young | Director | Nov 2010 |
| Kathy Laporte | Director | Nov 2010 |
| Nicholas Simon | Director | Nov 2010 |
| Sundar Kodijalam | Director | Nov 2010 |